IBRX
ImmunityBio, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +9.1% ·
share flow +11.0% ·
net new positions +8.3%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 104 | +6 | 153.81M | $1.35B | +10 | −6 |
| Q1 2026 | 103 | +11 | 130.83M | $998.92M | +19 | −8 |
| Q4 2025 | 91 | -1 | 143.54M | $283.94M | n/a | −1 |
| Q3 2025 | 15 | 0 | 77.60M | $190.89M | +2 | −2 |
| Q2 2025 | 12 | +1 | 58.35M | $154.05M | +1 | n/a |
| Q1 2025 | 8 | 0 | 12.96M | $39.01M | +1 | −1 |
| Q4 2024 | 8 | +1 | 14.27M | $36.54M | +2 | −1 |
| Q3 2024 | 6 | 0 | 5.93M | $22.06M | +1 | −1 |
| Q2 2024 | 6 | n/a | 4.42M | $27.95M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 21.82M | n/a | $57.60M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 17.77M | n/a | $46.91M | 0.0% | n/c | 1 | SEC ↗ ×11 |
| 3 | State Street Global Advisors ✦ (passive) | 7.62M | +0.4% | $20.11M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 5.78M | +34.7% | $15.25M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 3.24M | +654.8% | $8.56M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 6 | Two Sigma Investments ✦ | 802.56K | +3272.1% | $2.12M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 786.23K | +64.4% | $2.08M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 237.15K | New | $626,068 | 0.0% | New | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 159.16K | +258.1% | $420,188 | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 10 | T. Rowe Price ✦ | 115.00K | +74.0% | $304,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 11 | Gotham Asset Management ✦ | 16.22K | -64.0% | $42,831 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | Fidelity (FMR) ✦ | 14.14K | n/a | $37,332 | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| D. E. Shaw & Co. | $626,068 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 383 holders, 176.43M shares, $1.31B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 25.00K sh · $268,760
Director · 81.06K sh · $851,088
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
24.7% of class · View original SEC filing ↗